Geron Corporation (GERN) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-02

How it makes money

Payors pay because patients with lower-risk MDS need RYTELO to manage transfusion-dependent anemia.

Payors pay because patients with lower-risk myelodysplastic syndromes, or MDS, need RYTELO to manage anemia that requires four or more red blood cell units over eight weeks.

Clinical adoption by physicians and strong insurance coverage drive the final results.

What growth costs

Geron must invest heavily in commercial teams and new clinical trials to grow.

To grow, the company is investing in U.S. commercial efforts and marketing channels like digital promotion.

It is also funding the Phase 3 IMpactMF clinical trial to test the drug for other blood cancers.

About Geron Corporation

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Other companies in Biotechnology